Clinical significance of anti-Yt(b). Report of a case using a 51-chromium red cell survival study

Journal Article · Sun May 01 04:00:00 EDT 1988 · Transfusion (Philadelphia); (United States)

DOI:https://doi.org/10.1046/j.1537-2995.1988.28388219157.x· OSTI ID:7025594

Levy, G J; Selset, G; McQuiston, D; Nance, S J; Garratty, G; Smith, L E; Goldfinger, D

Several published reports have documented the variable survival of Yt(a+) red cells (RBC) in patients with anti-Yt(a) as measured by 51-Chromium (Cr)-labeled RBC survival studies. Similar studies with anti-Yt(b) have not been reported. A /sup 51/Cr-labeled RBC survival study was performed using Yt(b+) RBCs and a monocyte monolayer assay in a young hemodialysis patient who required chronic transfusion therapy and who had developed anti-Yt(b). The survival of the transfused RBCs was 100 and 93 percent at 1 and 24 hours, respectively, with a half life of 21 days at termination of the study (normal, 28 to 32 days). These results showed no evidence of rapid destruction of the Yt(b+) RBCs, indicating that this patient could be transfused safely with blood from Yt(b+) donors. Long-term survival of the /sup 51/Cr-labeled Yt(b+) RBCs was shortened moderately, however, a finding that correlated with a slightly abnormal monocyte monolayer assay test.

• Research Organization: Cedars-Sinai Medical Center, Los Angeles, CA (USA)
• OSTI ID: 7025594
• Journal Information: Transfusion (Philadelphia); (United States), Journal Name: Transfusion (Philadelphia); (United States) Vol. 28:3; ISSN TRANA
• Country of Publication: United States
• Language: English

Related Subjects

550901* -- Pathology-- Tracer Techniques
59 BASIC BIOLOGICAL SCIENCES
BETA DECAY RADIOISOTOPES
BIOLOGICAL HALF-LIFE
BIOLOGICAL MATERIALS
BLOOD
BLOOD CELLS
BLOOD GROUPS
BODY
BODY FLUIDS
CHROMIUM 51
CHROMIUM ISOTOPES
DIALYSIS
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
ERYTHROCYTES
EVEN-ODD NUCLEI
INTERMEDIATE MASS NUCLEI
ISOTOPES
KIDNEYS
MATERIALS
NUCLEI
ORGANS
PATHOGENESIS
PATIENTS
RADIOISOTOPES
SEPARATION PROCESSES
SURVIVAL CURVES
THERAPY
TRANSFUSIONS
UROGENITAL SYSTEM DISEASES